AntibioticDB

Highest development stage: Approved

Development active

Gram-negative activity

Combination therapy

Mechanism of Action/Target pathogen: Complicated urinary tract infections, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia/ ventilator-associated bacterial pneumonia, febrile neutropenia, bacteremia, acute pyelonephritis (some indications specifically target infections caused by carbapenem- resistant Enterobacteriaceae )

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10871

Source: http://www.vabomere.com

Citation (1): https://aac.asm.org/content/62/1/e01904-17

Citation (2): https://journals.sagepub.com/doi/abs/10.1177/1060028018763288?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=aopd

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/441130

Vaborbactam, RPX7009 + meropenem (Vabomere)

Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (heterocyclic boron)

Rempex Pharmaceuticals (wholly owned subsidiary of The Medicines Co.), USA

2013